HC Wainwright Issues Negative Forecast for IOVA Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share estimate for Iovance Biotherapeutics from ($0.26) to ($0.30), while maintaining a "Buy" rating and a target price of $9.00.
• The stock recently reported a negative earnings result of ($0.33) per share for the last quarter, falling short of analysts’ consensus of ($0.29) by ($0.04).
• Despite the negative forecast, the consensus rating from analysts is a "Hold" with an average price target of $10.80, reflecting a mix of buy, hold, and sell ratings among analysts.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Iovance Biotherapeutics in a research report issued on Wednesday, October 29th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($0.30) for the quarter, down from their prior forecast of ($0.26). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.07) EPS and FY2027 earnings at ($0.79) EPS.

Other research analysts have also issued research reports about the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Iovance Biotherapeutics in a research note on Wednesday, October 8th. Chardan Capital reduced their target price on Iovance Biotherapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wells Fargo & Company reduced their target price on Iovance Biotherapeutics from $18.00 to $14.00 and set an "overweight" rating on the stock in a report on Friday, August 8th. The Goldman Sachs Group cut shares of Iovance Biotherapeutics from a "neutral" rating to a "sell" rating in a research report on Tuesday, July 15th. Finally, Zacks Research raised shares of Iovance Biotherapeutics to a "hold" rating in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Iovance Biotherapeutics has an average rating of "Hold" and an average price target of $10.80.

Iovance Biotherapeutics Stock Down 2.5%

NASDAQ:IOVA opened at $1.95 on Friday. The stock's 50 day moving average price is $2.24 and its two-hundred day moving average price is $2.33. The firm has a market capitalization of $705.62 million, a price-to-earnings ratio of -1.59 and a beta of 0.83. Iovance Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.04). The business had revenue of $59.95 million during the quarter, compared to the consensus estimate of $67.14 million. Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS.

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of IOVA. Vontobel Holding Ltd. acquired a new stake in Iovance Biotherapeutics in the third quarter valued at $26,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Iovance Biotherapeutics in the 3rd quarter valued at about $27,000. WealthTrust Axiom LLC grew its position in shares of Iovance Biotherapeutics by 80.0% in the 2nd quarter. WealthTrust Axiom LLC now owns 18,000 shares of the biotechnology company's stock valued at $31,000 after buying an additional 8,000 shares during the last quarter. Accredited Investors Inc. acquired a new position in shares of Iovance Biotherapeutics in the first quarter worth approximately $33,000. Finally, Diversify Wealth Management LLC acquired a new position in shares of Iovance Biotherapeutics in the second quarter worth approximately $34,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.